Arovella Therapeutics CEO Dr Michael Baker Outlines 2024 Clinical Milestones with JustStocks Video Following $12.5 Million Raise

Arovella Therapeutics Limited (ASX: ALA) CEO Dr Michael Baker speaks with JustStocks Video following news the company has raised $12.5 million via a placement to institutional and sophisticated investors, including a specialist healthcare/biotechnology fund. Baker says the capital raised will be used to take the lead program ALA-101 into Phase 1 clinical trials and generate data in patients with CD19+ blood cancers. He says the additional funds will also allow for the continued development of Arovella’s solid tumour products.

Articles of Interest